Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction

Launched by SHANGHAI TONG REN HOSPITAL · Mar 21, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called a PCSK9 inhibitor, specifically alirocumab, can help patients' hearts recover after a serious heart attack known as STEMI. The trial involves two groups of patients: one group will receive the PCSK9 inhibitor right after a procedure to restore blood flow to the heart and then every two weeks for three months, while the other group will receive standard treatment. Researchers will track how well the heart recovers using special imaging tests and blood tests over the next six months.

To participate in this study, patients need to be between 18 and 80 years old and have had a STEMI within the last 24 hours. They should also be planning to have a specific procedure called PPCI to open blocked arteries. However, those who are allergic to the medication, have certain serious health issues, or are pregnant cannot join. Participants can expect regular check-ups and tests to monitor their heart health and any side effects from the treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The age is greater than 18 years old and less than or equal to 80 years old.
• • 2. Patients who are clinically diagnosed with STEMI onset within 24 hours and who are planning to undergo PPCI .
• • 3. Signed informed consent.
• Exclusion Criteria:
• • 1. Patients who are allergic to PCSK9 inhibitors.
• • 2. Multivessel disease planned for selective intervention within half a year.
• • 3. Patients who have previously undergone revascularization.
• • 4. Pregnant women or women who plan to become pregnant in the next 2 years.
• • 5. Patients whose life expectancy is less than 1 year.
• • 6. Severe liver or kidney dysfunction (ALT\>5 times ULA, eGFR\<15ml/min/1.73m2)
• • 7. Known active malignant tumor diseases.
• • 8. Patients considered by the investigator to be unsuitable to participate in this study.